about
Rho-associated kinases in tumorigenesis: re-considering ROCK inhibition for cancer therapyNovel Insights into the Roles of Rho Kinase in CancerInhibition of STAT5: a therapeutic option in BCR-ABL1-driven leukemiaCooperative anti-invasive effect of Cdc42/Rac1 activation and ROCK inhibition in SW620 colorectal cancer cells with elevated blebbing activityTargeting Cdc42 with the small molecule drug AZA197 suppresses primary colon cancer growth and prolongs survival in a preclinical mouse xenograft model by downregulation of PAK1 activityMyxoma virus oncolytic efficiency can be enhanced through chemical or genetic disruption of the actin cytoskeletonARF1 regulates the Rho/MLC pathway to control EGF-dependent breast cancer cell invasionSimultaneous and independent tuning of RhoA and Rac1 activity with orthogonally inducible promoters.Suppression of chemotaxis by SSeCKS via scaffolding of phosphoinositol phosphates and the recruitment of the Cdc42 GEF, Frabin, to the leading edge.RHOA inactivation enhances Wnt signalling and promotes colorectal cancer.A Novel Pharmacologic Activity of Ketorolac for Therapeutic Benefit in Ovarian Cancer Patients.LIM kinase inhibitors disrupt mitotic microtubule organization and impair tumor cell proliferation.Cucurbitacin I inhibits Rac1 activation in breast cancer cells by a reactive oxygen species-mediated mechanism and independently of Janus tyrosine kinase 2 and P-Rex1.Rho GTPase RhoJ is Associated with Gastric Cancer Progression and Metastasis.The Rac-GAP Bcr is a novel regulator of the Par complex that controls cell polarity.Portulacerebroside A inhibits adhesion, migration, and invasion of human leukemia HL60 cells and U937 cells through the regulation of p38/JNK signaling pathway.PLCE1 Promotes Esophageal Cancer Cell Progression by Maintaining the Transcriptional Activity of Snail.Association of LPP and TAGAP Polymorphisms with Celiac Disease Risk: A Meta-Analysis.DLC1-dependent parathyroid hormone-like hormone inhibition suppresses breast cancer bone metastasis.Rho GTPases in animal cell cytokinesis: an occupation by the one percent.Rho-kinase: regulation, (dys)function, and inhibition.Reversing synapse loss in Alzheimer's disease: Rho-guanosine triphosphatases and insights from other brain disorders.Inhibition of invasion and metastasis of human liver cancer HCCLM3 cells by portulacerebroside A.Rho GTPases, their post-translational modifications, disease-associated mutations and pharmacological inhibitors.Transcriptional profiling of GBM invasion genes identifies effective inhibitors of the LIM kinase-Cofilin pathway.RhoA and RhoC differentially modulate estrogen receptor α recruitment, transcriptional activities, and expression in breast cancer cells (MCF-7).Cdc42-dependent F-actin dynamics drive structuration of the demarcation membrane system in megakaryocytes.Theoretical study on the interaction of pyrrolopyrimidine derivatives as LIMK2 inhibitors: insight into structure-based inhibitor design.Plk1 regulates contraction of postmitotic smooth muscle cells and is required for vascular homeostasis.Discovery of potent and selective MRCK inhibitors with therapeutic effect on skin cancer.An RNAi screen of Rho signalling networks identifies RhoH as a regulator of Rac1 in prostate cancer cell migration.
P2860
Q24631326-2DFD08E5-0379-4C4C-8FFF-EA81D4863B9DQ26771368-CFEF30F3-597C-48E0-A5F5-F302E808FDF2Q27004027-4D1836C0-1177-4359-AE1F-378FA22E8141Q27312206-83A21BC2-1A82-46BC-994B-8AF031B8AF81Q28302802-8056F67A-0D02-46B7-9ECF-2B15BE7C7180Q28538172-FD2718F9-6902-496F-B0A5-B3061F41A986Q30560783-8F422F48-C6F5-49CC-9410-5C9FEEC6A653Q34077909-519318FC-483F-47C5-9A4C-B93C98376D6BQ34428538-4E786A3A-DE1F-42EA-826A-CA156C83FA28Q34628925-B208ECD2-7186-4103-A786-AE164C46A540Q36279606-BB183C74-8FC0-4C67-8D36-5C0DA2F9A09BQ36629339-8DEAC18F-6DCA-4CEB-99B7-B9199FA6ABF6Q36776754-B9425A9F-5D22-41C7-8DE2-C9884CA9F384Q37133691-8837D2AD-8837-4D31-BFCD-6D7D63AE2EA9Q37387817-9D7E6B62-9781-4722-B4AC-D376F9F5944EQ37420745-1A3FB90F-6DD3-4CA4-B315-DDB9EC177C6BQ37613600-C4AEC0EB-5913-4704-9DE4-AD0221974170Q37678467-9A1935C1-6E45-4DA7-9358-88381A9CF769Q37679939-1BE9AD4F-9AB4-4FB6-BF6D-3969BEE41D77Q38050708-69FD1432-0318-422E-99B9-57DF9D60FB53Q38129373-39A9CE99-85F7-4EFC-A642-14E70985A341Q38318392-01C06A03-0B68-47A5-902B-CC14F5F98533Q38932403-061FADD2-2808-44F6-8C53-0ED25E8B91BBQ38933808-8F97BBB4-5EF1-4ED1-926D-DE9045B51E60Q38955095-44EE6A06-247C-43AA-9B81-7AF55325AD14Q39085721-3FA51471-F277-4823-8580-58E28D14B2FFQ39909113-D84BB232-A787-4DCD-AFCB-501C71140566Q44274365-31CFFD90-44FE-4B6B-80D1-E0FDC62C982EQ48152427-701E0152-626E-4A3E-8B2E-482A2748F8FDQ48519050-8D773617-EF07-40E4-A3D2-BDFC55BD9A58Q52671388-FB662FE2-457F-42FB-8682-F24957C9EAFA
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Targeting Rho GTPase signaling for cancer therapy.
@en
Targeting Rho GTPase signaling for cancer therapy.
@nl
type
label
Targeting Rho GTPase signaling for cancer therapy.
@en
Targeting Rho GTPase signaling for cancer therapy.
@nl
prefLabel
Targeting Rho GTPase signaling for cancer therapy.
@en
Targeting Rho GTPase signaling for cancer therapy.
@nl
P2860
P356
P1433
P1476
Targeting Rho GTPase signaling for cancer therapy.
@en
P2093
Katerina Mardilovich
Mark Baugh
P2860
P304
P356
10.2217/FON.11.143
P407
P577
2012-02-01T00:00:00Z